Levosimendan Treatment for Heart Failure: A Systematic Review and Meta-Analysis

Journal of Cardiothoracic and Vascular Anesthesia

Volumn 29, Issue 6, 2015, Pages 1415-1425

  Gong, Bojun ^a   Li, Zicheng ^a   Yat Wong, Philip Ching ^a  

^a THE FIRST AFFILIATED HOSPITAL OF JINAN UNIVERSITY   (China)

Author keywords

complications; dobutamine; heart failure; levosimendan; meta analysis; mortality; outcomes

Indexed keywords

DOBUTAMINE; LEVOSIMENDAN; PLACEBO; CARDIOTONIC AGENT; HYDRAZONE DERIVATIVE; PYRIDAZINE DERIVATIVE; SIMENDAN;

ACUTE HEART FAILURE; ANGINA PECTORIS; ARTICLE; CARDIOGENIC SHOCK; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR PARAMETERS; CARDIOVASCULAR RISK; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; ECHOCARDIOGRAPHY; EXTRASYSTOLE; FOLLOW UP; FORWARD HEART FAILURE; HEADACHE; HEART ARRHYTHMIA; HEART FAILURE; HEART HEMODYNAMICS; HEART INDEX; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE ISCHEMIA; HEART STROKE VOLUME; HEART VENTRICLE EXTRASYSTOLE; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPOKALEMIA; HYPOTENSION; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; MEAN ARTERIAL PRESSURE; META ANALYSIS; MIGRAINE; NAUSEA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SYSTEMATIC REVIEW; SYSTEMIC VASCULAR RESISTANCE; THORAX PAIN; URINARY TRACT INFECTION; VOMITING; MORTALITY; PROCEDURES; TREATMENT OUTCOME;

CARDIOTONIC AGENTS; HEART FAILURE; HUMANS; HYDRAZONES; PYRIDAZINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84983157103     PISSN: 10530770     EISSN: 15328422     Source Type: Journal    
DOI: 10.1053/j.jvca.2015.03.023     Document Type: Article

References (58)

1. N Sharpe, and R Doughty Epidemiology of heart failure and ventricular dysfunction Lancet 352 Suppl 1 1998 SI3 S7
2. AM Brown, and JG Cleland Influence of concomitant disease on patterns of hospitalization in patients with heart failure discharged from Scottish hospitals in 1995 Eur Heart J 19 1998 1063 1069
3. L De Luca, WS Colucci, MS Nieminen, and et al. Evidence-based use of levosimendan in different clinical settings Eur Heart J 27 2006 1908 1920
4. + channels J Pharmacol Sci 104 2007 1 5
5. + channel in rat arterial myocytes Eur J Pharmacol 333 1997 249 259
6. SB Thacker Meta-analysis. A quantitative approach to research integration JAMA 259 1988 1685 1689
7. L.A. Rasmussen, and et al. Effects of levosimendan in patients with left ventricular hypertrophy undergoing aortic valve replacement Acta Anaesthesiol Scand 59 2015 65 77
8. MT Slawsky, WS Colucci, SS Gottlieb, and et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure Circulation 102 2000 2222 2227
9. VS Moiseyev, P Poder, N Andrejevs, and et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction-A randomized, placebo-controlled, double-blind study (RUSSLAN) Eur Heart J 23 2002 1422 1432
10. N Mantel, and W Haenszel Statistical aspects of the analysis of data from retrospective studies of disease J Natl Cancer Inst 22 1959 719 748
11. F Follath, JG Cleland, H Just, and et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): A randomised double-blind trial Lancet 360 2002 196 202
12. A Mebazaa, MS Nieminen, M Packer, and et al. Levosimendan vs Dobutamine for Patients With Acute Decompensated Heart Failure The SURVIVE Randomized Trial JAMA 297 2007 1883 1891
13. M Packer, W Colucci, L Fisher, and et al. Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure JACC Heart failure 1 2013 103 111
14. MS Nieminen, J Akkila, G Hasenfuss, and et al. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure J Am Coll Cardiol 36 2000 1903 1912
15. A Tasal, M Erturk, H Uyarel, and et al. Utility of the neutrophil to lymphocyte ratio for predicting in-hospital mortality after levosimendan infusion in patients with acute decompensated heart failure J Cardiol 63 2014 418 423
16. Y Cavusoglu, M Tek, A Birdane, and et al. Both levosimendan and dobutamine treatments result in significant reduction of NT-proBNP levels, but levosimendan has better and prolonged neurohormonal effects than dobutamine Int J Cardiol 127 2008 e188 e191
17. D Qarawani, A Cohen, M Nahir, and et al. Facilitation of left ventricular function recovery post percutaneous coronary intervention by levosimendan Int J Cardiol 168 2013 237 242
18. D Farmakis, JT Parissis, V Bistola, and et al. Plasma B-type natriuretic peptide reduction predicts long-term response to levosimendan therapy in acutely decompensated chronic heart failure Int J Cardiol 139 2010 75 79
19. A Dominguez-Rodriguez, S Samimi-Fard, MJ Garcia-Gonzalez, and et al. Effects of levosimendan versus dobutamine on left ventricular diastolic function in patients with cardiogenic shock after primary angioplasty Int J Cardiol 128 2008 214 217
20. MJ Bonios, JV Terrovitis, SG Drakos, and et al. Comparison of three different regimens of intermittent inotrope infusions for end stage heart failure Int J Cardiol 159 2012 225 229
21. 2+-sensitizer levosimendan improves oxidative damage, BNP and pro-inflammatory cytokine levels in patients with advanced decompensated heart failure in comparison to dobutamine Eur J Heart Fail 7 2005 882 887
22. CH Bergh, B Andersson, U Dahlström, and et al. Intravenous levosimendan vs. dobutamine in acute decompensated heart failure patients on beta-blockers Eur J Heart Fail 12 2010 404 410
23. A Mebazaa, MS Nieminen, GS Filippatos, and et al. Levosimendan vs. dobutamine: Outcomes for acute heart failure patients on beta-blockers in SURVIVE Eur J Heart Fail 11 2009 304 311
24. L De Luca, P Proietti, A Celotto, and et al. Levosimendan improves hemodynamics and coronary flow reserve after percutaneous coronary intervention in patients with acute myocardial infarction and left ventricular dysfunction Am Heart J 150 2005 563 568
25. L Tritapepe, V De Santis, D Vitale, and et al. Levosimendan pre-treatment improves outcomes in patients undergoing coronary artery bypass graft surgery Br J Anaesth 102 2009 198 204
26. JT Parissis, A Karavidas, V Bistola, and et al. Effects of levosimendan on flow-mediated vasodilation and soluble adhesion molecules in patients with advanced chronic heart failure Atherosclerosis 197 2008 278 282
27. JT Parissis, I Andreadou, SL Markantonis, and et al. Effects of Levosimendan on circulating markers of oxidative and nitrosative stress in patients with advanced heart failure Atherosclerosis 195 2007 e210 e215
28. P Flevari, JT Parissis, D Leftheriotis, and et al. Effect of levosimendan on ventricular arrhythmias and prognostic autonomic indexes in patients with decompensated advanced heart failure secondary to ischemic or dilated cardiomyopathy Am Heart J 98 2006 1641 1645
29. JT Parissis, I Paraskevaidis, V Bistola, and et al. Effects of levosimendan on right ventricular function in patients with advanced heart failure Am Heart J 98 2006 1489 1492
30. JT Parissis, F Panou, D Farmakis, and et al. Effects of levosimendan on markers of left ventricular diastolic function and neurohormonal activation in patients with advanced heart failure Am Heart J 96 2005 423 426
31. JT Parissis, S Adamopoulos, C Antoniades, and et al. Effects of levosimendan on circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure Am Heart J 93 2004 1309 1312
32. S Adamopoulos, JT Parissis, EK Iliodromitis, and et al. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure Am Heart J 98 2006 102 106
33. RL Levin, MA Degrange, R Porcile, and et al. The calcium sensitizer levosimendan gives superior results to dobutamine in postoperative low cardiac output syndrome Rev Esp Cardiol 61 2008 471 479
34. D Duman, F Palit, E Simsek, and et al. Effects of levosimendan versus dobutamine on left atrial function in decompensated heart failure Can J Cardiol 25 2009 e353 e356
35. S Mavrogeni, G Giamouzis, E Papadopoulou, and et al. A 6-month follow-up of intermittent levosimendan administration effect on systolic function, specific activity questionnaire, and arrhythmia in advanced heart failure J Card Fail 13 2007 556 559
36. JT Parissis, G Filippatos, D Farmakis, and et al. Levosimendan for the treatment of acute heart failure syndromes Expert Opin Pharmacother 6 2005 2741 2751
37. A Zangrillo, G Biondi-Zoccai, A Mizzi, and et al. Levosimendan reduces cardiac troponin release after cardiac surgery: A meta-analysis of randomized controlled studies J Cardiothorac Vasc Anesth 23 2009 474 478
38. G Landoni, G Biondi-Zoccai, M Greco, and et al. Effects of levosimendan on mortality and hospitalization. A meta-analysis of randomized controlled studies Crit Care Med 40 2012 634 646
39. G Koster, J Wetterslev, C Gluud, and et al. Effects of levosimendan for low cardiac output syndrome in critically ill patients: Systematic review with meta-analysis and trial sequential analysis Intensive Care Med 41 2015 203 221
40. R.D. Covello, and et al. A Bayesian network meta-analysis on the effect of inodilatory agents on mortality Br J Anaesth 114 2015 746 756
41. MS Nieminen, J Altenberger, T Ben-Gal, and et al. Repetitive use of levosimendan for treatment of chronic advanced heart failure: Clinical evidence, practical considerations, and perspectives: An expert panel consensus Int J Cardiol 174 2014 360 367
42. M Kivikko, S Antila, J Eha, and et al. Pharmacokinetics of levosimendan and its metabolites during and after a 24-hour continuous infusion in patients with severe heart failure Int J Clin Pharmacol Ther 40 2002 465 471
43. T Ahmad, M Fiuzat, GM Felker, and et al. Novel biomarkers in chronic heart failure Nat Rev Cardiol 9 2002 347 359
44. K Kangawa, and H Matsuo Purification and complete amino acid sequence of alpha-human atrial natriuretic polypeptide (alpha-hANP) Biochem Biophys Res Commun 118 1984 131 139
45. K Maeda, T Tsutamoto, A Wada, and et al. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction Am Heart J 135 1998 825 832
46. E Lubien, A DeMaria, P Krishnaswamy, and et al. Utility of B-natriuretic peptide in detecting diastolic dysfunction - comparison with Doppler velocity recordings Circulation 105 2002 595 601
47. T Mueller, A Gegenhuber, and M Haltmayer Levosimendan reduces plasma amino terminal proBNP in patients with decompensated heart failure Int J Cardiol 104 2005 355 356
48. J Lilleberg, A Laine, T Palkama, and et al. Duration of the haemodynamic action of a 24-h infusion of levosimendan in patients with congestive heart failure Eur J Heart Fail 9 2007 75 82
49. AS McLean, SJ Huang, M Nalos, and et al. Duration of the beneficial effects of levosimendan in decompensated heart failure as measured by echocardiographic indices and B-type natriuretic peptide J Cardiovasc Pharmacol 46 2005 830 835
50. S Kyrzopoulos, S Adamopoulos, JT Parissis, and et al. Levosimendan reduces plasma B-type natriuretic peptide and interleukin 6, and improves central hemodynamics in severe heart failure patients Int J Cardiol 99 2005 409 413
51. A Gegenhuber, T Mueller, F Firlinger, and et al. Time course of B-Type natriuretic peptide (BNP) and N-terminal ProBNP changes in patients with decompensated heart failure Clin Chem 50 2004 454 456
52. H Duygu, F Ozerkan, S Nalbantgil, and et al. Effect of levosimendan on E/E' ratio in patients with ischemic heart failure Int J Cardiol 123 2008 201 203
53. J Meluzin, L Spinarova, J Bakala, and et al. Pulsed Doppler tissue imaging of the velocity of tricuspid annular systolic motion - A new, rapid, and non-invasive method of evaluating right ventricular systolic function Eur Heart J 22 2001 340 348
54. JT Parissis, S Adamopoulos, and D Farmakis Effects of serial levosimendan infusions on left ventricular performance and plasma biomarkers of myocardial injury and neurohormonal and immune activation in patients with advanced heart failure Heart 92 2006 1768 1772
55. JN Nanas, PP Papazoglou, JV Terrovitis, and et al. Hemodynamic effects of levosimendan added to dobutamine in patients with decompensated advanced heart failure refractory to dobutamine alone Am J Cardiol 94 2004 1329 1332
56. M Kivikko, L Lehtonen, WS Colucci, and et al. Sustained hemodynamic effects of intravenous levosimendan Circulation 107 2003 81 86
57. G Zemljic, M Bunc, AP Yazdanbakhsh, and et al. Levosimendan improves renal function in patients with advanced chronic heart failure awaiting cardiac transplantation J Card Fail 13 2007 417 421
58. G Landoni, A Mizzi, G Biondi-Zoccai, and et al. Reducing mortality in cardiac surgery with levosimendan: A meta-analysis of randomized controlled trials J Cardiothorac Vasc Anesth 24 2010 51 57